• OPEN AN ACCOUNT
Indian Indices
Sensex
83,919.71 897.96
( 1.08%)
Global Indices
Nasdaq
48,502.41 -615.65
(-1.25%)
Dow Jones
6,987.82 -209.01
(-2.90%)
Hang Seng
56,657.02 -2,787.19
(-4.69%)
Nikkei 225
10,369.59 -83.09
(-0.79%)
Forex
USD-INR
93.34 -0.08
(-0.09%)
EUR-INR
102.47 -0.06
(-0.06%)
GBP-INR
122.55 -0.48
(-0.39%)
JPY-INR
0.58 0.00
(-0.32%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

Natco Pharma's Hyderabad unit concludes USFDA inspection
Nov 21,2026

Natco Pharma announced conclusion of US FDA Inspection at its formulation plant located at Kothur, Hyderabad. 

The U.S. Food and Drug Administration (USFDA) conducted an inspection of the Company's Formulation manufacturing facility located in Kothur, Hyderabad, India, from 12 November to 20 November 2026.

Upon conclusion of the inspection, the Company received seven (7) observations in the Form-483. The Company believes that the observations are procedural in nature and is confident of addressing these observations comprehensively within stipulated timelines.